This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Subramanian, J. Articles by Govindan, R. Search for Related Content PubMed PubMed Citation Articles by Subramanian, J. Articles by Govindan, R.

Lung Cancer in Never Smokers: A Review

Janakiraman Subramanian, Ramaswamy Govindan

From the Department of Medicine and Alvin J. Siteman Cancer Center, Washington University School of Medicine, St Louis, MO

Address reprint requests to Ramaswamy Govindan, MD, Division of Oncology, 4960 Children's Place, St Louis, MO 63110; e-mail: rgovinda{at}im.wustl.edu

Lung cancer is the leading cause of cancer-related death in the United States. Although tobacco smoking accounts for the majority of lung cancer, approximately 10% of patients with lung cancer in the United States are lifelong never smokers. Lung cancer in the never smokers (LCINS) affects women disproportionately more often than men. Only limited data are available on the etiopathogenesis, molecular abnormalities, and prognosis of LCINS. Several etiologic factors have been proposed for the development of LCINS, including exposure to radon, cooking fumes, asbestos, heavy metals, and environmental tobacco smoke, human papillomavirus infection, and inherited genetic susceptibility. However, the relative significance of these individual factors among different ethnic populations in the development of LCINS has not been well-characterized. Adenocarcinoma is the predominant histologic subtype reported with LCINS. Striking differences in response rates and outcomes are seen when patients with advanced non–small-cell lung cancer (NSCLC) who are lifelong never smokers are treated with epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors such as gefitinib or erlotinib compared with the outcomes with these agents in patients with tobacco-associated lung cancer. Interestingly, the activating mutations in the EGFR-TK inhibitors have been reported significantly more frequently in LCINS than in patients with tobacco-related NSCLC. This review will summarize available data on the epidemiology, risk factors, molecular genetics, management options, and outcomes of LCINS.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				G. Mountzios, D. Planchard, B. Besse, P. Validire, P. Girard, C. Devisme, M.-A. Dimopoulos, J.-C. Soria, and P. Fouret Mitogen-Activated Protein Kinase Activation in Lung Adenocarcinoma: A Comparative Study between Ever Smokers and Never Smokers Clin. Cancer Res., July 1, 2008; 14(13): 4096 - 4102. [Abstract] [Full Text] [PDF]

				P. Song, H. S. Sekhon, X. W. Fu, M. Maier, Y. Jia, J. Duan, B. J. Proskosil, C. Gravett, J. Lindstrom, G. P. Mark, et al. Activated Cholinergic Signaling Provides a Target in Squamous Cell Lung Carcinoma Cancer Res., June 15, 2008; 68(12): 4693 - 4700. [Abstract] [Full Text] [PDF]

				S. Dubey and C. A. Powell Update in Lung Cancer 2007 Am. J. Respir. Crit. Care Med., May 1, 2008; 177(9): 941 - 946. [Full Text] [PDF]

				F. de Marinis and F. Grossi Clinical Evidence for Second- and Third-Line Treatment Options in Advanced Non-Small Cell Lung Cancer Oncologist, January 1, 2008; 13(suppl_1): 14 - 20. [Abstract] [Full Text] [PDF]

				A. F. Gazdar and M. J. Thun Lung Cancer, Smoke Exposure, and Sex J. Clin. Oncol., February 10, 2007; 25(5): 469 - 471. [Full Text] [PDF]